CN1154496C - 奥氮平和氟西汀在制备治疗对抗治疗的严重抑郁症的药物中的应用 - Google Patents

奥氮平和氟西汀在制备治疗对抗治疗的严重抑郁症的药物中的应用 Download PDF

Info

Publication number
CN1154496C
CN1154496C CNB998090719A CN99809071A CN1154496C CN 1154496 C CN1154496 C CN 1154496C CN B998090719 A CNB998090719 A CN B998090719A CN 99809071 A CN99809071 A CN 99809071A CN 1154496 C CN1154496 C CN 1154496C
Authority
CN
China
Prior art keywords
treatment
olanzapine
fluoxetine
acid
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998090719A
Other languages
English (en)
Chinese (zh)
Other versions
CN1311681A (zh
Inventor
G��D�����շ�ɭ
G·D·托勒夫森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1311681A publication Critical patent/CN1311681A/zh
Application granted granted Critical
Publication of CN1154496C publication Critical patent/CN1154496C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Medicines Containing Plant Substances (AREA)
CNB998090719A 1998-05-22 1999-05-21 奥氮平和氟西汀在制备治疗对抗治疗的严重抑郁症的药物中的应用 Expired - Fee Related CN1154496C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8644498P 1998-05-22 1998-05-22
US60/086444 1998-05-22

Publications (2)

Publication Number Publication Date
CN1311681A CN1311681A (zh) 2001-09-05
CN1154496C true CN1154496C (zh) 2004-06-23

Family

ID=22198612

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998090719A Expired - Fee Related CN1154496C (zh) 1998-05-22 1999-05-21 奥氮平和氟西汀在制备治疗对抗治疗的严重抑郁症的药物中的应用

Country Status (24)

Country Link
EP (1) EP0958824A3 (enExample)
JP (1) JP2002516282A (enExample)
KR (1) KR20010043730A (enExample)
CN (1) CN1154496C (enExample)
AU (1) AU761510B2 (enExample)
BR (1) BR9911049A (enExample)
CA (1) CA2332814C (enExample)
CZ (1) CZ20004279A3 (enExample)
EA (1) EA004539B1 (enExample)
HK (1) HK1040055B (enExample)
HR (1) HRP20000797A2 (enExample)
HU (1) HUP0101901A3 (enExample)
ID (1) ID26861A (enExample)
IL (1) IL139592A (enExample)
MY (1) MY127938A (enExample)
NO (1) NO20005885L (enExample)
NZ (1) NZ507980A (enExample)
PL (1) PL344331A1 (enExample)
SK (1) SK17512000A3 (enExample)
TR (1) TR200003443T2 (enExample)
TW (1) TWI226829B (enExample)
UA (1) UA78181C2 (enExample)
WO (1) WO1999061027A1 (enExample)
ZA (1) ZA200006815B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1133299A1 (en) * 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
SI1237553T1 (sl) * 1999-12-06 2006-06-30 Lundbeck & Co As H Kombinacija inhibitorja ponovnega navzema serotonina in antagonista 5-ht 2c?, inverznega agonista ali delnega agonista
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
MXPA03006003A (es) * 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.
MXPA05000294A (es) 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
GB0229583D0 (en) * 2002-12-19 2003-01-22 Cipla Ltd A process for preparing duloxetine and intermediates for use therein
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
AU2003295235B2 (en) 2002-12-27 2008-06-19 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
AU2004269858A1 (en) * 2003-09-04 2005-03-17 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and Loxapine
AU2004283196B2 (en) 2003-09-17 2011-08-25 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds
EP1713486A4 (en) 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
WO2005056056A2 (en) * 2003-12-15 2005-06-23 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
CA2620333A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2439201B1 (en) 2006-06-16 2013-08-07 H. Lundbeck A/S Compounds with combined sert, 5-ht3 and 5-ht1a activity
HRP20141008T1 (hr) * 2007-02-09 2015-01-02 Alphapharm Pty Ltd Oblik doziranja koji sadrži dva aktivna farmaceutska sastojka u razliäśitim fizikalnim oblicima
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN105769875A (zh) * 2014-12-22 2016-07-20 扬子江药业集团上海海尼药业有限公司 复方奥氮平盐酸氟西汀胶囊的制备方法
CN108938645A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种抗精神病药物组合物
CN111084778B (zh) * 2019-12-31 2022-06-24 北京鑫开元医药科技有限公司 一种奥氮平盐酸氟西汀胶囊及其制备方法
CN114569566A (zh) * 2020-12-02 2022-06-03 四川科瑞德制药股份有限公司 一种盐酸米那普仑制剂的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000103A1 (en) * 1990-06-28 1992-01-09 Beecham Group Plc Pharmaceutical preparations
FR2716680B1 (fr) * 1994-02-25 1996-04-05 Adir Nouveaux dérivés de benzodioxane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
JP2000506859A (ja) * 1996-03-11 2000-06-06 イーライ・リリー・アンド・カンパニー 双極性障害の処置方法
CZ296263B6 (cs) * 1996-03-25 2006-02-15 Eli Lilly And Company Farmaceutická kompozice pro lécení bolesti a jejípouzití
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Also Published As

Publication number Publication date
CN1311681A (zh) 2001-09-05
EP0958824A3 (en) 1999-12-01
KR20010043730A (ko) 2001-05-25
AU4008699A (en) 1999-12-13
HUP0101901A3 (en) 2002-06-28
BR9911049A (pt) 2001-02-06
AU761510B2 (en) 2003-06-05
JP2002516282A (ja) 2002-06-04
EA004539B1 (ru) 2004-06-24
HK1040055B (zh) 2005-04-01
WO1999061027A1 (en) 1999-12-02
ZA200006815B (en) 2002-01-14
EA200001218A1 (ru) 2001-06-25
TWI226829B (en) 2005-01-21
CZ20004279A3 (cs) 2001-09-12
UA78181C2 (en) 2007-03-15
ID26861A (id) 2001-02-15
NO20005885D0 (no) 2000-11-21
HUP0101901A2 (hu) 2001-11-28
NO20005885L (no) 2001-01-17
IL139592A (en) 2005-08-31
IL139592A0 (en) 2002-02-10
EP0958824A2 (en) 1999-11-24
NZ507980A (en) 2003-10-31
MY127938A (en) 2007-01-31
HK1040055A1 (en) 2002-05-24
HRP20000797A2 (en) 2001-10-31
SK17512000A3 (sk) 2002-02-05
PL344331A1 (en) 2001-11-05
TR200003443T2 (tr) 2001-03-21
CA2332814C (en) 2008-11-04
CA2332814A1 (en) 1999-12-02

Similar Documents

Publication Publication Date Title
CN1154496C (zh) 奥氮平和氟西汀在制备治疗对抗治疗的严重抑郁症的药物中的应用
CN1162156C (zh) 奥氮平与氟西汀在制备治疗精神病药物中的用途
CN1302207A (zh) 双相性精神障碍的联合治疗
CN1113436A (zh) 药物反应的增效作用
CN1366881A (zh) 用雌激素激动剂/拮抗剂治疗某些癌症的方法
CN1267423C (zh) 作为ip拮抗剂的取代的2－苯基氨基咪唑啉苯基酮衍生物
CN1655784A (zh) 有效的选择性阿片受体调制剂化合物的用途
CN1049336C (zh) 异恶唑衍生物在制备治疗肠应激综合征的组合物中的用途
CN1430609A (zh) 取代的1－氨基烷基内酰胺化合物及其作为毒蕈碱受体拮抗剂的用途
CN1452497A (zh) Ssri和雌激素制剂的联合药物形式
CN1871029A (zh) 含有类糜蛋白酶抑制剂作为有效成分的药物
CN1809545A (zh) N－苯基－哌嗪衍生物和预防或者治疗5HT2c受体相关疾病的方法
US6960577B2 (en) Combination therapy for treatment of refractory depression
CN1117092C (zh) 氮杂双环化合物,其药物组合物及医药用途
HK1048072A1 (zh) 用於治疗抑郁症或预防认知功能退化的方法和药盒
CN1750817A (zh) 米那普仑(1s,2r)对映体在药品制备方面的用途
CN1774433A (zh) 作为胰高血糖素受体拮抗剂的取代的3－氰基噻吩乙酰胺
CN1268949A (zh) 稠合噻吩化合物及其医药用途
CN1956714A (zh) 用于治疗下泌尿道病症的α－氨基酰胺衍生物
CN1726039A (zh) 用于治疗情绪障碍的喹诺酮衍生物和5－羟色胺再摄取抑制剂
CN1109749A (zh) 抑制子宫纤维变性的方法
CN1662544A (zh) 对血清素受体具有亲和力、可用作治疗剂的新型四环芳基磺酰吲哚、其制备方法及其药物组合物
CN1705654A (zh) 使用对映体富集的西酞普兰去甲基和二去甲基代谢产物治疗抑郁症以及其它中枢神经病症的方法
CN1639124A (zh) 作为毒蕈碱受体拮抗剂的氨基四氢萘衍生物
CN1332740A (zh) 用于抗抑郁疗法的5－ht1拮抗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1040055

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040623

Termination date: 20110521